Advertisement


Nirav N. Shah, MD, on Mantle Cell Lymphoma: Follow-up Data on Pirtobrutinib in Pretreated Disease

2023 ASCO Annual Meeting

Advertisement

Nirav N. Shah, MD, of the Medical College of Wisconsin, discusses the efficacy and safety of pirtobrutinib, a highly selective, noncovalent BTK inhibitor, studied for more than 3 years in the BRUIN trial. The results showed that the use of pirtobrutinib continues to have durable efficacy and a favorable safety profile in heavily pretreated patients with relapsed or refractory mantle cell lymphoma and prior BTK inhibitor therapy. Responses were observed in patients with high-risk disease features, including blastoid/pleomorphic variants, elevated Ki67 index, and TP53 mutations (Abstract 7514).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Nirav N. Shah: So mantle cell lymphoma is a disease that sort of is felt to be a relapsing remitting disease, which means that most patients are going to relapse in their lifetime. Now, while we have very, very good therapies for relapse mantle cell, which generally include covalent BTK inhibitors. For those patients who progress after covalent BTK inhibitors, options are limited. We have treatments like CAR T-cell therapy, but not all patients are healthy enough, fit enough, or are in an area where CAR T-cell therapy is accessible. So pirtobrutinib was studied as part of the BRUIN trial to look specifically at patients with B-cell malignancies. And the data being reported is looking at the cohort of patients with mantle cell lymphoma who received this drug in a relapsed refractory setting. Unlike other BTK inhibitors pirtobrutinib is a non-covalent reversible inhibitor showing that it has a different mechanism of action than the BTK inhibitors that are currently being used in the second line setting. As part of the BRUIN study, whether or not you had prior BTK exposure was not an exclusion, and so actually the majority of patients who received pirtobrutinib, 90 of them, actually had prior BTK exposure, which is an unmet need in mantle cell lymphoma. Despite seeing a different BTK inhibitor, first, the overall response rate with pirtobrutinib was 58% in this heavily pretreated group, which is really just exciting to have another oral agent be effective in that patient population. Not only was it effective, but there were also durable responses. And so now in this sort of two year long term follow-up, we know that the median duration of response for those patients who were responding to therapy was 18 months, and the median overall survival was nearly 2 years. This data actually led to this drug now being FDA approved and in this clinical setting and available, and part of that is because the safety profile that's demonstrated in the BRUIN study in this patient population was actually quite favorable. The toxicities were low and the traditional BTK toxicities, things like atrial fibrillation, hypertension, and bleeding were actually seen at very low rates, such that may occur actually in a general patient population. In conclusion, I think that pirtobrutinib represents a novel mechanism of action in inhibiting the BTK pathway and allowing patients that have failed other covalent BTK inhibitors to continue receiving an oral medication that has now shown incredible efficacy, safety, and durability.

Related Videos

Lung Cancer

Narjust Florez, MD, and Filippo Gustavo Dall’Olio, MD, on NSCLC: New Findings on Tumor Fraction, Durvalumab, and Survival

Narjust Florez, MD, of Dana-Farber Cancer Institute, and Filippo Gustavo Dall’Olio, MD, of Institut Gustave Roussy, discuss circulating tumor DNA tumor fraction, and its link to survival in patients with advanced non–small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial. Tumor fraction was positive in 16% of patients randomly assigned to receive durvalumab in the study. This population seems to have a limited benefit from maintenance durvalumab after induction chemotherapy (Abstract 2516).

Colorectal Cancer

Cathy Eng, MD, and Thejus Jayakrishnan, MD, on Colorectal Cancer: Metabolomic Differences in Young-Onset vs Average-Onset Disease

Cathy Eng, MD, of Vanderbilt-Ingram Cancer Center, and Thejus Jayakrishnan, MD, of the Cleveland Clinic Taussig Cancer Institute, discuss significant differences in the citrate cycle, a core pathway of cellular metabolism associated with colorectal cancer. Metabolomic differences impacted by environmental exposures (arginine biosynthesis and dietary red meat) were also noted, suggesting possible links with younger age of onset in this disease (Abstract 3510).

Solid Tumors

Funda Meric-Bernstam, MD, on HER2-Expressing Solid Tumors: Efficacy and Safety of Trastuzumab Deruxtecan

Funda Meric-Bernstam, MD, of The University of Texas MD Anderson Cancer Center, discusses interim results from the DESTINY-PanTumor02 trial, the first tumor-agnostic global study of fam-trastuzumab deruxtecan-nxki (T-DXd) in a broad range of HER2-expressing solid tumors. This agent showed an encouraging overall response rate, particularly in patients with IHC 3+ expression; durable clinical benefit; and a manageable safety profile in these heavily pretreated patients. T-DXd may be a potential new treatment option for this population (Abstract LBA3000).

Leukemia

LaQuisa C. Hill, MD, on Relapsed or Refractory T-ALL: New Data on CD5 CAR T Cells

LaQuisa C. Hill, MD, of Baylor College of Medicine, Houston Methodist Hospital, discusses study findings showing that CD5 chimeric antigen receptor (CAR) T cells may induce clinical responses in heavily treated patients with relapsed or refractory T-cell acute lymphoblastic leukemia. Manufacturing CD5 CAR T cells with tyrosine kinase inhibitors seemed to improve their potency and antitumor activity (Abstract 7002).

Lymphoma

Nirav N. Shah, MD, on DLBCL: New Data on Split-Dose R-CHOP for Older Patients

Nirav N. Shah, MD, of the Medical College of Wisconsin, discusses phase II results showing that split-dose R-CHOP offers older patients with diffuse large B-cell lymphoma (DLBCL) an equivalent dose intensity as R-CHOP-21 through a fractionated dosing schedule, improving tolerability. At the end of treatment for these older patients, a complete response rate of 71% was comparable to outcomes with R-CHOP in younger patients with the disease (Abstract 7554).

Advertisement

Advertisement




Advertisement